1Ishimura T, Fujisawa M, Isotani S, et al. Transforming growth factor-beta1 expression in early biopsy specimen predicts long-term graft function following pediatric renal transplantation[J]. Clin-Transplant ,2001,15(3) : 185-191.
2B, Ktanar MS,Bloom RD, et al. Transforming growth factor-beta levels in htanan allograft chronic fibrosis correhte with rate of dedine in renal function[J]. Transplantation, 1999, 68(6):785-790.
3Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation[J]. Nature, 1992,357(4) : 695-697.
4Weir MR, Ward MT, Blahut SA, et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy[J]. Kidney lnt, 2001 59(9) : 1567-1573.
5Olyaei AJ, de Mattos AM, Bennett WM. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies[J].Curr Opin Crit Care, 2001,7(3) : 384-389.
6Weir MR. Methods and outcomes of calcineurin inhibitor reduction or withdrawal in patients with chronic allograft nephropathy after the first year posttransplantation[ J ]. Transplant Proc, 2001, 33(13) : 19S-28S.
7Mele TS, Halloran PF. The use of myeophenolate mofetil in transplant recipients[J], Immunopharmacology,2000,47(2) :215-245.
8Tran HB, Acharya MK, Mckay DB, et al. Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids[J]. J Am Soc Nephrol, 2000, 11 (8) :1903-1909.
9Pierre EW, Kathy A. Evaluation of the new AxSYM cyclosporine assay: comparison with TDx monoclonal whole blood and emit cyclosporine assays[J].Clin Chem, 1999,45 (3) : 432.
10Werner S. Perfommnce and specificity of monoclonal immunoassays for cyclosporine moniloring: How specific is specific [J].Clin Chem, 1999,45(3) :371.
